Financial Comparison: Keros Therapeutics (NASDAQ:KROS) and argenex (NASDAQ:ARGX)

argenex (NASDAQ:ARGX) and Keros Therapeutics (NASDAQ:KROS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

Institutional and Insider Ownership

60.3% of argenex shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares argenex and Keros Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
argenex	31.66%	47.70%	40.12%
Keros Therapeutics	-256.60%	-21.85%	-19.83%

Volatility and Risk

argenex has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for argenex and Keros Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0	6	21	1	2.82
Keros Therapeutics	1	2	4	1	2.62

argenex currently has a consensus price target of $1,158.76, indicating a potential upside of 18.60%. Keros Therapeutics has a consensus price target of $21.40, indicating a potential upside of 124.58%. Given Keros Therapeutics’ higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than argenex.

Valuation & Earnings

This table compares argenex and Keros Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$5.82 billion	10.55	$1.29 billion	$28.66	34.09
Keros Therapeutics	$244.06 million	0.77	$87.01 million	($2.82)	-3.38

argenex has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Summary

argenex beats Keros Therapeutics on 10 of the 14 factors compared between the two stocks.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.